SYDRA AG

Using AI and in vivo screens to develop novel geroprotectors

SYDRA AG is a Swiss longevity biotech developing an AI-assisted, phenotype-first drug discovery platform for age-associated diseases. We generate or prioritize small molecules with AI, validate lifespan and healthspan effects in vivo (*C. elegans* ? elderly mice), then identify targets and mechanisms to build de-risked preclinical drug candidates. Our primary customers are pharma and biotech companies seeking partner-ready assets for licensing or co-development. SYDRA has validated 5 geroprotectors in worms, with 2 leads improving lifespan/healthspan in elderly mice. The market opportunity is the >$1T global medicines market driven by age-related diseases.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

15.11.2025

Validation contract with SPRIN-D

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (10'000) 2023

Website